Mr. Stephen Lemieux reports

TITAN MEDICAL ANNOUNCES DELAY IN FIRST QUARTER 2023 FILINGS

As a result of a delay in filing its annual financial statements, the related management's discussion and analysis, and annual information form, and the accompanying chief executive officer and chief financial officer certification for its financial year ended Dec. 31, 2022, Titan Medical Inc. will also be delayed in the filing of its financial statements, the related management's discussion and analysis, and the accompanying chief executive officer and chief financial officer certification for its first quarter ended March 31, 2023, and now expects to file the Q1 filing documents by June 9, 2023. As announced on May 15, 2023, the company expects to file the annual filing documents by May 31, 2023.

On March 22, 2023, and as further updated on April 3, 2023, April 17, 2023, May 1, 2023, and May 15, 2023, the company announced that under National Policy 12-203 (Management Cease Trade Orders) it had applied to the Ontario Securities Commission requesting a management cease trade order be imposed in respect of the late filing of the annual filing documents. The MCTO was granted by the OSC on April 3, 2023.

The MCTO restricts all trading in and all acquisitions of the securities of the company, directly or indirectly, by the chief executive officer and the chief financial officer of the company until two full business days following the receipt by the OSC of the annual filing documents and any other filings the company is required to make under Ontario securities laws, including the Q1 filings, or upon the further order of the director of the OSC. The MCTO does not affect the ability of shareholders who are not named in the MCTO to trade their securities.

About Titan Medical Inc.

Titan Medical (Toronto Stock Exchange: TMD), a medical device company headquartered in Toronto, Ont., with operations in Chapel Hill, N.C., was focused on enhancing robotic-assisted surgery (RAS) using innovative technology through a single access point. On Nov. 30, 2022, the company announced the commencement of a strategic review process that considered a full range of strategic alternatives, including a corporate sale, merger or other business combination, a sale of all or a portion of the company's assets, a strategic investment, or other significant transaction. On Feb. 8, 2023, the company announced that none of the parties approached as part of the strategic review process expressed an interest in pursuing a transaction with the company. As a result, the company initiated various cost-cutting measures and announced that its board of directors had determined to prioritize the sale of all or a portion of the company's assets, and subsequently on Feb. 14, 2023, the company announced that it had laid off a number of senior management personnel.

We seek Safe Harbor.